GLP-3 (Retatrutide)

Description

GLP-3 is Genefyx’s designation for retatrutide, a single synthetic peptide engineered as a triple agonist: one molecule that binds and activates three distinct metabolic receptors at once – the GLP-1 receptor, the GIP (glucose-dependent insulinotropic polypeptide) receptor, and the glucagon receptor. These receptors sit at the center of how the body senses nutrients and coordinates insulin secretion, glucose handling, and energy expenditure, and are normally engaged by the incretin hormones released by the gut after a meal.

Because it recruits all three pathways simultaneously rather than one in isolation, retatrutide is of interest in metabolic research as a tool for studying how combined incretin and glucagon signaling influences glucose regulation, the appetite-control circuits of the hypothalamus, and whole-body energy metabolism. It represents the most recent generation of incretin research molecules. Genefyx supplies it strictly as a research reference material, mass-spectrometry verified and accompanied by a certificate of analysis.

How it works

Simultaneous agonism of three incretin/metabolic receptor pathways — a next-generation metabolic research peptide.

Research context

Leading-edge obesity and metabolic research molecule; the hero across the Genefyx site.

Handling

Lyophilized powder. Certificate of analysis, ≥99% purity.

Research use only. Not for animal or human consumption. Not approved or evaluated by the FDA — not a drug, supplement, or therapy. Price shown is a placeholder pending final pricing.